🔎 Trials Near Me

Home › Osteoarthritis › NCT07353931

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

RecruitingPhase 3

A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening
* Have a stable body weight (less than 5% body weight change) for 90 days prior to screening
* Have tried at least once to lose weight through diet but were unsuccessful
* Have osteoarthritis of the knee and at least one of the following conditions:

  * Be over 50 years old
  * Have morning knee stiffness that lasts about 30 minutes
  * Have a crackling or grinding sound or feeling in the knee

Exclusion Criteria:

* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening)
* Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
* Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
* Have an active knee infection
* Have had within 90 days prior to screening:

  * heart attack
  * stroke
  * coronary artery revascularization
  * unstable angina, or
  * hospitalization due to congestive heart failure
* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
* Have taken medications or alternative remedies intended for weight loss within 90 days of screening

About the study

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

What is being tested

Sponsor: Eli Lilly and Company · Participants: 900 · Started: Feb 9, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07353931

Locations in the U.S.

AlabamaAMR Clinical, Mobile
ArizonaCare Access - 801 South Power Road, Mesa, Mesa
Elite Pain and Spine Institute - South Crimson Road, Mesa
Elite Clinical Studies, LLC, Phoenix
Tucson Orthopaedic Institute - North Wyatt Drive, Tucson
CaliforniaArk Clinical Research - Fountain Valley, Fountain Valley
Wolverine Clinical Trials, Santa Ana
Encompass Clinical Research, Spring Valley
Diablo Clinical Research, Inc., Walnut Creek
ColoradoSkylight Health Research - Colorado Springs, Colorado Springs
FloridaWestside Center for Clinical Research, Jacksonville
Care Access - St. Petersburg, St. Petersburg
Conquest Research, Winter Park
GeorgiaOrita Clinical Research, Decatur
IdahoMedical Research Partners, Ammon
IllinoisGreat Lakes Clinical Trials - Ravenswood, Chicago
IndianaQualmedica Research, LLC, Evansville
KansasAMR Clinical, Newton
KentuckyMonroe Biomedical Research - Louisville, Louisville
MassachusettsSkylight Health Research - Burlington, Burlington
Care Access - Quincy, Quincy
New YorkEllipsis Research Group - Brooklyn - 7th Street, Brooklyn
Rochester Clinical Research - Buffalo, Buffalo
NYC Research INC, Long Island City
Rochester Clinical Research, LLC, Rochester
OklahomaCentral States Research, Tulsa
PennsylvaniaKeystone Clinical Studies, Plymouth Meeting
TexasJCCT - Juno Bellaire Site, Bellaire
Epic Medical Research - DeSoto, DeSoto
Valley Institute of Research - Fort Worth, Fort Worth
Care Access - Houston, Houston
Endeavor Clinical Trials, San Antonio
VIP Trials, San Antonio
Consano Clinical Research, LLC, Shavano Park
Texas Valley Clinical Research, Weslaco
UtahAMR Clinical, South Jordan
VirginiaCharlottesville Medical Research, Charlottesville
WashingtonParamount Clinical Research - Data Point Clinical Research, Kirkland

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.